XML 60 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 30, 2016
Nov. 09, 2016
Feb. 10, 2016
Jan. 04, 2016
Jan. 31, 2017
Sep. 30, 2016
Jun. 30, 2017
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration             $ 63,000 $ 125,000        
Secured loan facility, amount borrowed               19,429,000        
Paid-in-kind interest                 $ 2,604,000      
Gain on extinguishment of debt             (830,000) (830,000)        
Insulin Put                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration                   $ 10,200,000    
Sanofi-Aventis Deutschland GmbH | Put Option                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Payment for insulin put option         $ 30,600,000         $ 30,600,000    
Aventisub LLC                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Outstanding loan balance forgiven   $ 72,000,000                    
Receptor                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Nonrefundable payments               400,000        
Nonrefundable option exercise and license fee $ 1,000,000                      
Reduction in research and development expense               400,000        
Deferred revenue - nonrefundable license fee             1,000,000 $ 1,000,000        
Deferred revenue recognition period               4 years        
Net revenue from collaboration             100,000 $ 100,000        
License and Collaboration Agreement with Sanofi                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Profits and losses sharing percentage               35.00%        
Termination date       Apr. 04, 2016                
Maximum secured loan facility                       $ 175,000,000
Senior notes, effective interest rate                       8.50%
Gain on extinguishment of debt   $ 500,000                    
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Deferred revenue - nonrefundable license fee             150,000,000 $ 150,000,000        
Net revenue from collaboration               $ 172,000,000        
Profits and losses sharing percentage               65.00%        
Milestone receivable             $ 25,000,000 $ 25,000,000        
Deferred cost                     $ 13,500,000  
Secured loan facility, amount borrowed     $ 17,900,000               44,500,000  
Secured loan facility, amount owed           $ 71,200,000            
Paid-in-kind interest           $ 5,800,000            
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Deferred revenue - nonrefundable license fee                     17,500,000  
Net revenue from collaboration               17,500,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration               150,000,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration               25,000,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration               25,000,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration               19,400,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Net revenue from collaboration               $ (64,900,000)        
Company's total portion of loss sharing                     $ 57,700,000